Furthermore, PITX1 was strongly linked to the presence of ERG fusion: nearly 80% of ERG positive tumor samples (71.6% low and 6.9% high) but only 55% of ERG negative tumor samples (51.5% low and 3.3% high) (p < 0.0001; Tables S3 and S4) showed immune-histochemical PITX1 expression. The gene discussed is PITX1; the disease is neoplasm.